ES2243016T3 - Antagonistas de receptores de integrinas. - Google Patents

Antagonistas de receptores de integrinas.

Info

Publication number
ES2243016T3
ES2243016T3 ES98963915T ES98963915T ES2243016T3 ES 2243016 T3 ES2243016 T3 ES 2243016T3 ES 98963915 T ES98963915 T ES 98963915T ES 98963915 T ES98963915 T ES 98963915T ES 2243016 T3 ES2243016 T3 ES 2243016T3
Authority
ES
Spain
Prior art keywords
alkyl
amino
aryl
group
hydroxycarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98963915T
Other languages
English (en)
Inventor
Mark E. Duggan
Robert S. Meissner
John H. Hutchinson
Wasyl Halczenko
Ben C. Askew
Paul J. Coleman
Michael A. Patane
Jiabing Wang
James J. Perkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9810182.7A external-priority patent/GB9810182D0/en
Priority claimed from GBGB9810882.2A external-priority patent/GB9810882D0/en
Priority claimed from GBGB9810892.1A external-priority patent/GB9810892D0/en
Priority claimed from GBGB9811283.2A external-priority patent/GB9811283D0/en
Priority claimed from GBGB9812686.5A external-priority patent/GB9812686D0/en
Priority claimed from GBGB9822331.6A external-priority patent/GB9822331D0/en
Priority claimed from GBGB9822701.0A external-priority patent/GB9822701D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2243016T3 publication Critical patent/ES2243016T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Vending Machines For Individual Products (AREA)

Abstract

Un compuesto que tiene una fórmula estructural seleccionada entre el grupo constituido por y en las que la línea a trazos a representa un enlace simple o doble, con la condición de que, cuando a representa un enlace doble, los átomos de carbono del doble enlace estén sustituidos sólo con R10 y R12; X se selecciona entre el grupo constituido por Y se selecciona entre el grupo constituido por -CH2)m-, -(CH2)m-O-(CH2)n-, -(CH2)m-NR4-(CH2)n-, -(CH2)m-S-(CH2)n-, -(CH2)m-SO-(CH2)n-, -(CH2)m-SO2-(CH2)n-, -(CH2)m-O-(CH2)n-O-(CH2)p-, -(CH2)m-O-(CH2)n-NR4-(CH2)p- -(CH2)m-NR4-(CH2)-NR4-(CH2)p- y -(CH2)m-NR4-(CH2)n-O-(CH2)p-, en el que cualquier átomo de carbono del metileno (CH2) de Y que no sea de R4 puede estar sustituido con uno o dos sustituyentes R3; y en el que R1 se selecciona independientemente entre el grupo constituido por hidrógeno, halógeno, alquilo C1-10, cicloalquilo C3-8, cicloheteroalquilo C3-8, cicloalquilo C3-8 alquilo C1-6, cicloheteroalquilo C3-8 alquilo C1-6, arilo, aril alquil C1- 8, amino, aminoalquilo C1-8, acil C3-8 amino, acil C1-3 amino alquilo C3-8, (alquil C1-6)p amino, (alquil C1-6)p amino alquilo C1-8, alcoxi C1-4, alcoxi C1-4 alquilo C1-6, hidroxicarbonilo, hidroxicarbonil alquilo C1-6, alcoxi C1-3 carbonilo, alcoxi C1-3 carbonilo alquilo C1-6, hidroxicarbonil alquiloxi C1-6, hidroxi, hidroxi alquilo C1-6, alquil C1-6 oxi alquilo C1- 6, nitro, ciano, trifluorometilo, trifluorometoxi, trifluoroetoxi, alquilo C1-8-S(O)p, (alquil C1-8)p aminocarbonilo, alquil C1-8 oxicarbonilamino, (alquil C1-8)p aminocarboniloxi, (aril alquil C1-8)p amino, (aril)p amino, aril alquil C1-8 sulfonilamino y alquil C1-8 sulfonilamino; o dos sustituyentes R1, cuando están en el mismo átomo de carbono, son tomados junto con el átomo de carbono al que están unidos para formar un grupo carbonilo.
ES98963915T 1997-12-17 1998-12-14 Antagonistas de receptores de integrinas. Expired - Lifetime ES2243016T3 (es)

Applications Claiming Priority (31)

Application Number Priority Date Filing Date Title
US6991097P 1997-12-17 1997-12-17
US69910P 1997-12-17
US7919798P 1998-03-24 1998-03-24
US79197P 1998-03-24
US7994498P 1998-03-30 1998-03-30
US79944P 1998-03-30
US8039798P 1998-04-02 1998-04-02
US80397P 1998-04-02
US8325198P 1998-04-27 1998-04-27
US83251P 1998-04-27
GBGB9810182.7A GB9810182D0 (en) 1998-05-13 1998-05-13 Vitronectin receptor antagonists
GB9810182 1998-05-13
GBGB9810882.2A GB9810882D0 (en) 1998-05-20 1998-05-20 Vitronectin receptor antagonists
GBGB9810892.1A GB9810892D0 (en) 1998-05-20 1998-05-20 Vitronectin receptor antagonists
GB9810892 1998-05-20
GB9810882 1998-05-20
GBGB9811283.2A GB9811283D0 (en) 1998-05-26 1998-05-26 Vironectin receptor antagonists
GB9811283 1998-05-26
GB9812686 1998-06-12
GBGB9812686.5A GB9812686D0 (en) 1998-06-12 1998-06-12 Vitronectin receptor antagonists
US9258898P 1998-07-13 1998-07-13
US9262498P 1998-07-13 1998-07-13
US92588P 1998-07-13
US92624P 1998-07-13
US9994898P 1998-09-11 1998-09-11
US99948P 1998-09-11
GB9822331 1998-10-13
GBGB9822331.6A GB9822331D0 (en) 1998-10-13 1998-10-13 Vitronectin receptor antagonists
GB9822701 1998-10-16
GBGB9822701.0A GB9822701D0 (en) 1998-10-16 1998-10-16 Intergrin receptor antagonists
PCT/US1998/026568 WO1999031099A1 (en) 1997-12-17 1998-12-14 Integrin receptor antagonists

Publications (1)

Publication Number Publication Date
ES2243016T3 true ES2243016T3 (es) 2005-11-16

Family

ID=27585232

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98963915T Expired - Lifetime ES2243016T3 (es) 1997-12-17 1998-12-14 Antagonistas de receptores de integrinas.

Country Status (23)

Country Link
EP (1) EP1040111B1 (es)
JP (2) JP3589633B2 (es)
KR (2) KR20010024748A (es)
AT (1) ATE298338T1 (es)
AU (1) AU741769B2 (es)
BG (1) BG104601A (es)
CA (1) CA2315189C (es)
DK (1) DK1040111T3 (es)
EA (1) EA003095B1 (es)
EE (1) EE200000360A (es)
ES (1) ES2243016T3 (es)
HU (1) HUP0100178A3 (es)
IL (1) IL136314A0 (es)
IS (1) IS5513A (es)
NO (1) NO317975B1 (es)
NZ (1) NZ504896A (es)
PE (1) PE20000010A1 (es)
PL (1) PL341095A1 (es)
PT (1) PT1040111E (es)
SI (1) SI1040111T1 (es)
SK (1) SK9162000A3 (es)
TR (1) TR200001752T2 (es)
WO (1) WO1999031099A1 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU736026B2 (en) * 1997-12-17 2001-07-26 Merck & Co., Inc. Integrin receptor antagonists
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
JP2002522540A (ja) * 1998-08-13 2002-07-23 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
CN1398189A (zh) * 1998-12-23 2003-02-19 G.D.西尔公司 用于治疗肿瘤形成的放疗与cox－2抑制剂的联合治疗
HUP0203338A2 (hu) 1999-04-13 2003-03-28 Abbott Gmbh & Co. Kg Integrin receptor ligandumok
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
DK1187592T3 (da) 1999-06-02 2007-11-05 Merck & Co Inc Alfa v-integrinreceptorantagonister
DE19936780A1 (de) * 1999-08-09 2001-02-15 Basf Ag Neue Antagonisten von Integrinrezeptoren
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
JP2003510360A (ja) 1999-10-04 2003-03-18 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
CZ20021508A3 (cs) * 1999-11-08 2002-10-16 Merck & Co., Inc. Způsob výroby imidazolidinonových derivátů
US6407241B1 (en) 1999-11-08 2002-06-18 Merck & Co., Inc. Process and intermediates for the preparation of imidazolidinone αv integrin antagonists
GB2356630A (en) 1999-11-10 2001-05-30 Merck & Co Inc Intermediates used in the preparation of tetrahydronaphthyridine
JP2003514908A (ja) 1999-11-23 2003-04-22 メルク エンド カムパニー インコーポレーテッド テトラヒドロ−［１，８］−ナフチリジンに向けた方法および中間体
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
WO2001053297A1 (en) 2000-01-20 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
DE60130910T2 (de) 2000-04-17 2008-07-10 Ucb Pharma, S.A. Enamin-derivate als zell-adhäsionsmoleküle
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
JP2004502762A (ja) 2000-07-07 2004-01-29 セルテック　アール　アンド　ディ　リミテッド 二環性ヘテロ芳香環を含有するインテグリンアンタゴニストとしてのスクエア酸誘導体
JP2004505110A (ja) 2000-08-02 2004-02-19 セルテック　アール　アンド　ディ　リミテッド ３位置換イソキノリン−１−イル誘導体
EP1322310A4 (en) * 2000-09-13 2004-09-15 Merck & Co Inc ALPHA-V integrin receptor Antagonist
AU2001292598B2 (en) 2000-09-14 2006-06-29 Merck & Co., Inc. Alpha V integrin receptor antagonists
WO2002053099A2 (en) * 2001-01-03 2002-07-11 Merck & Co., Inc. Methods and compositions for treating periodontal disease
ES2200617B1 (es) 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
ES2366775T3 (es) 2001-04-24 2011-10-25 Merck Patent Gmbh POLITERAPIA UTILIZANDO AGENTES ANTIANGIOGÉNICOS Y TNF(alfa).
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
EP1798224A1 (en) * 2004-10-05 2007-06-20 Shionogi Co., Ltd. Biaryl derivative
AU2007207465B2 (en) 2006-01-18 2012-12-06 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
DE102006024024A1 (de) 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
BRPI0806596A2 (pt) 2007-01-18 2013-07-23 Merck Patent Ges Mit Berchraenkter Haftung medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer
WO2009114776A2 (en) * 2008-03-14 2009-09-17 Visen Medical, Inc. Integrin targeting agents and methods of using same
DE102008060967A1 (de) 2008-12-06 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylsulfonyltriazolone und ihre Verwendung
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
EP2445534A2 (en) 2009-05-25 2012-05-02 Merck Patent GmbH Continuous administration of cilengitide in cancer treatments
PL2539326T3 (pl) 2010-02-27 2017-10-31 Bayer Ip Gmbh Połączone bis-arylem arylotriazolony i ich zastosowanie
DE102010040187A1 (de) 2010-09-02 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung
DE102010040924A1 (de) 2010-09-16 2012-03-22 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylacet- und Phenylpropanamide und ihre Verwendung
US8901144B2 (en) 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
WO2014124302A1 (en) 2013-02-07 2014-08-14 Scifluor Life Sciences, Llc Fluorinated integrin antagonists
EP3050878B1 (en) 2013-09-24 2021-10-27 FUJIFILM Corporation Novel nitrogen-containing compound or salt thereof, or metal complex thereof
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
KR20170081178A (ko) 2014-11-03 2017-07-11 바이엘 파마 악티엔게젤샤프트 히드록시알킬-치환된 페닐트리아졸 유도체 및 그의 용도
CN113855703B (zh) * 2014-12-10 2025-11-25 特里赛达公司 用于口服施用的质子结合聚合物
WO2016134223A2 (en) * 2015-02-19 2016-08-25 Scifluor Life Sciences, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
WO2017189828A1 (en) * 2016-04-27 2017-11-02 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof
US9988367B2 (en) 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
SG11201907820SA (en) 2017-02-28 2019-09-27 Morphic Therapeutic Inc Inhibitors of (alpha-v)(beta-6) integrin
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
CA3109534A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibiting .alpha.v .beta.6 integrin
UY38352A (es) 2018-08-29 2020-03-31 Morphic Therapeutic Inc Inhibidores de integrina alfavbeta6
EP3843727A4 (en) 2018-08-29 2022-08-17 Morphic Therapeutic, Inc. INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1598073A (en) * 1976-12-18 1981-09-16 Beecham Group Ltd 8,10,12-triazaprostaglandins
AU4806879A (en) * 1978-06-15 1979-12-20 Beecham Group Limited 1,2,4 triazole derivatives
DE3042466A1 (de) * 1980-11-11 1982-06-16 A. Nattermann & Cie GmbH, 5000 Köln N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
EP0531382A1 (en) * 1990-05-25 1993-03-17 G.D. Searle & Co. N-substituted-1,2,4-triazolone compounds for treatment of cardiovascular disorders
US5416099A (en) * 1991-10-29 1995-05-16 Merck & Co., Inc. Fibrinogen receptor antagonists
JP2001527506A (ja) * 1992-02-11 2001-12-25 スミスクライン・ビーチャム・コーポレイション ＣｏＡ−ＩＴおよびＰＡＦ阻害剤
CA2190870A1 (en) * 1994-05-27 1995-12-07 George D. Hartman Compounds for inhibiting osteoclast-mediated bone resorption

Also Published As

Publication number Publication date
JP3589633B2 (ja) 2004-11-17
EA200000653A1 (ru) 2000-12-25
DK1040111T3 (da) 2005-10-10
NO20003113L (no) 2000-08-16
EE200000360A (et) 2001-12-17
NO20003113D0 (no) 2000-06-16
TR200001752T2 (tr) 2000-12-21
NO317975B1 (no) 2005-01-17
AU741769B2 (en) 2001-12-06
EP1040111A1 (en) 2000-10-04
PE20000010A1 (es) 2000-01-29
EA003095B1 (ru) 2002-12-26
HUP0100178A2 (hu) 2001-11-28
JP2002508374A (ja) 2002-03-19
IS5513A (is) 2000-05-26
CA2315189A1 (en) 1999-06-24
PT1040111E (pt) 2005-10-31
HUP0100178A3 (en) 2002-12-28
SK9162000A3 (en) 2001-03-12
WO1999031099A1 (en) 1999-06-24
SI1040111T1 (en) 2005-10-31
CA2315189C (en) 2005-04-19
PL341095A1 (en) 2001-03-26
KR20010024748A (ko) 2001-03-26
IL136314A0 (en) 2001-05-20
NZ504896A (en) 2002-10-25
ATE298338T1 (de) 2005-07-15
EP1040111B1 (en) 2005-06-22
KR20030048081A (ko) 2003-06-18
BG104601A (bg) 2001-01-31
JP2004300158A (ja) 2004-10-28
AU1914499A (en) 1999-07-05

Similar Documents

Publication Publication Date Title
CO5310534A1 (es) Nuevos derivados de androstano anti-inflamatorios
ECSP077274A (es) Derivados de n-2 adamantanil-2-fenoxi-acetamida como inhibidores de deshidrogenasa 11-beta hidroxiesteroide
CO5580777A2 (es) Inhibidores de hidroxipirimidinona carboxamida n-sustituidos de vih integrasa
CO5271658A1 (es) Antagonistas del factor liberador de corticotropina
AR061370A1 (es) Derivados de imidazopirimidina
AR004972A1 (es) Compuesto quinolino 4-carboxamidas n-sustituidas, un procedimiento para su preparacion, el uso de los mismos para la fabricacion de un medicamento, una composicion farmaceutica y un antagonista nk-2/nk-3 combinado.
BR0108303A (pt) Derivados do 1h-imidazopiridina
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
AR030279A1 (es) Derivados de fenilamida para-amino sustituida activadora de la glucoquinasa, un procedimiento para su preparacion, composiciones farmaceuticas y el empleo de dichos derivados para la preparacion de medicamentos.
AR040336A1 (es) Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
AR047706A1 (es) Inhibidores de polimerasa viral
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
AR067443A1 (es) Derivados heterociclicos de n-benziloxazolidinonas potenciadores de receptores de glutamato mglur2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de trastornos del sistema nervioso central
EA200201259A1 (ru) Производные бензимидазола, их получение и терапевтическое применение
CO4900063A1 (es) Piridinas substituidas como inhibidores selectivos de ciclo- oxi-genasa2
AR047754A1 (es) Derivados de indol inhibidores de las polimerasas virales
AR010795A1 (es) Compuestos derivados de sulfonamidas, procedimiento para su preparacion y una composicion farmaceutica
AR022820A1 (es) Compuestos derivados de piridopiranoacepinas, en forma de isomeros geometricos u opticos puros o de mezcla de tales isomeros, procedimiento para su preparacion, medicamento y composicion farmaceutica.
AR073924A1 (es) Azepino[4, 5-b]indoles, una composicion farmaceutica y kits que los comprenden y su uso en la modulacion de un receptor de histamina.
MX9704880A (es) Derivados de quinuclidina novedosos y composicion medicinal de los mismos.
ES2422383T3 (es) Activadores de urea glucoquinasa
AR065249A1 (es) Derivados nitrogenados condensados de analogos de nucleosidos, composiciones farmaceuticas que los contienen y usos para tratar y/o prevenir infecciones virales.
SE0101579D0 (sv) New compounds